FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Recruiting · Phase 1 · NCT05614739
Conditions: Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
At a glance
- Research payments reported, 2025
- $3.8M
- U.S. investigators named
- 31
- Sites paid
- 28
- Planned or actual enrollment
- 677
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Vepugratinib (drug), Pembrolizumab (drug), enfortumab vedotin (drug), Trastuzumab Deruxtecan (drug), Midazolam (drug), Digoxin (drug), Rosuvastatin (drug)
- Dates
- Started 2023-01-12; completion 2027-06
- Results posted
- Not yet
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
From ClinicalTrials.gov, last updated 2026-11-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.8M in research payments for this study in 2025 (31 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexandra Drakaki, M.D Internal Medicine · Santa Monica, CA
- Nataliya Mar, MD Hematology & Oncology · Orange, CA
- Mamta Parikh, M.D., M.S. Hematology & Oncology · Sacramento, CA
- Abhishek Tripathi, M.D. Medical Oncology · Duarte, CA
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Mehmet A. Bilen, M.D. Hematology & Oncology · Atlanta, GA
- Umang Swami, MD Hematology & Oncology · Iowa City, IA
- Randy Sweis Hematology & Oncology · Chicago, IL
- Tareq Salous, MD Hematology & Oncology · Indianapolis, IN
- Brian T. Halbert, M.D. Hematology & Oncology · New Orleans, LA
- Victor T. Lin, MD, PHD Hematology & Oncology · Baton Rouge, LA
- Xin Gao, M.D. Hematology & Oncology · Boston, MA
- Noah M. Hahn, M.D. Hematology & Oncology · Baltimore, MD
- Yusra F. Shao, MD Hematology & Oncology · Detroit, MI
- Melissa A. Reimers, MD Medical Oncology · Saint Louis, MO
- Minas P. Economides, MD Medical Oncology · New York, NY
- Matthew D. Galsky, MD Medical Oncology · New York, NY
- Benjamin A. Gartrell, MD Internal Medicine · Bronx, NY
- Gopakumar V. Iyer, M.D. Internal Medicine · New York, NY
- Matthew I. Milowsky, MD Medical Oncology · New York, NY
- Alexander Z. Wei, MD Medical Oncology · New York, NY
- Abdul Rafeh Naqash, MD Hematology & Oncology · Oklahoma City, OK
- Leonard J. Appleman, MD Hematology & Oncology · Pittsburgh, PA
- Priyanka Chablani, M.D. Hematology & Oncology · Pittsburgh, PA
- Ronac Mamtani, MD Medical Oncology · Philadelphia, PA
- Kevin K. Zarrabi, M.D. Medical Oncology · Philadelphia, PA
- Neal Shore, DR Urology · Myrtle Beach, SC
- Benjamin Garmezy, MD Hematology & Oncology · Nashville, TN
- Jeff S. Russell, M.D., PH.D. Medical Oncology · Nashville, TN
- Arlene O. Siefker-radtke, M.D. Medical Oncology · Houston, TX
- Tian Zhang, M.D. Medical Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $392,774
- Mount Sinai School of Medicine $354,523
- Memorial Sloan-Kettering $348,635
- Dana Farber PArtners Cancer Care Inc $247,598
- Sarah Cannon Research Institute LLC $233,440
- Hospital of Univ of Pennsylvania, PA $220,578
- Washington University $197,843
- University of Chicago $178,856
- The University of Texas $166,120
- Emory University Hospital, GA $145,715
- City of Hope National Medical Ctr $145,540
- Adventhealth Orlando, FL $145,535
- Univ of Pittsburgh Cancer Institute Cancer Srvcs $141,697
- Karmanos Cancer Center, MI $127,629
- University of Utah Hospital and Clinics, UT $126,746
- The on Eoncology Research Network LLC $114,390
- New York University $79,443
- Ronald Reagan UCLA Medical Center, CA $78,502
- University of California Davis Medical Center, CA $56,033
- Indiana University $49,373
- Uci Health-Orange, CA $48,872
- Trustees of Columbia Univ in The City of Ny $44,982
- Thomas Jefferson University $42,346
- Johns Hopkins University $40,403
- University of North Carolina at Chapel Hill $32,935
- Ochsner Medical Center Acute, LA $24,500
- Biomedical Research Alliance of New York $15,185
- Carolina Urologic Research Center $3,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.